
Mark Lewis/netrf.org
Jun 19, 2025, 08:24
Mark Lewis Reflects on Progress in Pancreatic Neuroendocrine Tumor Therapies
Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, posted on X:
“Dr James Yao observes that, prior to 2011, the only FDA-approved systemic therapy for pancreatic neuroendocrine tumors was streptozocin!
What a remarkable decade-plus of progress in the field and yet, for our patients, we have miles to go before we sleep.”
More posts featuring Pancreatic Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 19, 2025, 08:24
Jun 19, 2025, 08:05
Jun 19, 2025, 08:01
Jun 19, 2025, 07:51
Jun 19, 2025, 07:49
Jun 19, 2025, 07:38